Christopher Hoyle

909 total citations
25 papers, 555 citations indexed

About

Christopher Hoyle is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Christopher Hoyle has authored 25 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Immunology. Recurrent topics in Christopher Hoyle's work include Inflammasome and immune disorders (6 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Christopher Hoyle is often cited by papers focused on Inflammasome and immune disorders (6 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Christopher Hoyle collaborates with scholars based in United Kingdom, United States and Japan. Christopher Hoyle's co-authors include David Brough, Gloria López‐Castejón, Martin Lowe, Yu Shi, Paula I. Seoane, Stuart M. Allan, Eloïse Lemarchand, Jack Green, John Rex and Jorge Mestre-Ferrándiz and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Christopher Hoyle

24 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Hoyle United Kingdom 13 260 99 57 52 51 25 555
Simona Bancos United States 13 162 0.6× 142 1.4× 54 0.9× 39 0.8× 58 1.1× 18 543
Ruizhen Jia China 14 208 0.8× 95 1.0× 33 0.6× 24 0.5× 63 1.2× 20 463
Shuang Yin China 14 236 0.9× 74 0.7× 88 1.5× 49 0.9× 28 0.5× 30 527
Jin Zhou China 17 316 1.2× 121 1.2× 84 1.5× 88 1.7× 27 0.5× 67 766
Rongpan Bai China 17 482 1.9× 66 0.7× 87 1.5× 55 1.1× 63 1.2× 33 910
Zhenzhen Deng China 16 216 0.8× 118 1.2× 71 1.2× 36 0.7× 56 1.1× 51 724
Alena V. Savenka United States 12 148 0.6× 66 0.7× 28 0.5× 35 0.7× 38 0.7× 22 464
Chuang Yuan China 16 301 1.2× 99 1.0× 82 1.4× 47 0.9× 60 1.2× 32 710
Kamlakar Tripathi India 10 125 0.5× 50 0.5× 75 1.3× 28 0.5× 36 0.7× 29 537
Fatemeh Hassani Iran 15 153 0.6× 76 0.8× 43 0.8× 68 1.3× 25 0.5× 25 823

Countries citing papers authored by Christopher Hoyle

Since Specialization
Citations

This map shows the geographic impact of Christopher Hoyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Hoyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Hoyle more than expected).

Fields of papers citing papers by Christopher Hoyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Hoyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Hoyle. The network helps show where Christopher Hoyle may publish in the future.

Co-authorship network of co-authors of Christopher Hoyle

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Hoyle. A scholar is included among the top collaborators of Christopher Hoyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Hoyle. Christopher Hoyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tapia, Víctor S., Ran Zhou, Christopher Hoyle, et al.. (2025). The role of 25-hydroxycholesterol in the pathophysiology of brain vessel dysfunction associated with infection and cholesterol dysregulation. Disease Models & Mechanisms. 18(9). 3 indexed citations
2.
Tapia, Víctor S., Paula I. Seoane, Hayley Bennett, et al.. (2024). Proximity labelling of pro-interleukin-1α reveals evolutionary conserved nuclear interactions. Nature Communications. 15(1). 6750–6750. 3 indexed citations
3.
Rivers‐Auty, Jack, Christopher Hoyle, Catherine B. Lawrence, et al.. (2024). C9orf72 dipeptides activate the NLRP3 inflammasome. Brain Communications. 6(5). fcae282–fcae282. 3 indexed citations
4.
Green, Jack, Christopher Hoyle, Lorna M. FitzPatrick, et al.. (2024). Brazilin is a natural product inhibitor of the NLRP3 inflammasome. iScience. 27(2). 108968–108968. 7 indexed citations
5.
Hoyle, Christopher, Jack Green, Fatima Martín‐Sánchez, et al.. (2023). Disruptions in endocytic traffic contribute to the activation of the NLRP3 inflammasome. Science Signaling. 16(773). eabm7134–eabm7134. 34 indexed citations
6.
Haley, Michael, Christopher Hoyle, Leo Zeef, et al.. (2023). The comparable tumour microenvironment in sporadic andNF2-related schwannomatosis vestibular schwannoma. Brain Communications. 5(4). fcad197–fcad197. 12 indexed citations
7.
Hoyle, Christopher, Jack Green, Stuart M. Allan, David Brough, & Eloïse Lemarchand. (2022). Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages. Immunology. 165(4). 460–480. 50 indexed citations
8.
Rivers‐Auty, Jack, Víctor S. Tapia, Claire White, et al.. (2021). Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation. Journal of Neuroscience. 41(13). 3025–3038. 55 indexed citations
9.
Seoane, Paula I., Christopher Hoyle, Yu Shi, et al.. (2020). The NLRP3–inflammasome as a sensor of organelle dysfunction. The Journal of Cell Biology. 219(12). 127 indexed citations
10.
Dyer, Matthew, et al.. (2020). The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer. Health Economics Review. 10(1). 10–10. 1 indexed citations
11.
Hoyle, Christopher, Alyssa Klein, Norah J. Shire, et al.. (2018). Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy. Annals of Oncology. 29. viii323–viii323. 1 indexed citations
12.
13.
Mann, Helen, Frank Andersohn, Tetsuya Mitsudomi, et al.. (2017). Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation. 38(4). 319–331. 16 indexed citations
14.
Andersohn, Frank, Helen Mann, Tetsuya Mitsudomi, et al.. (2016). Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI. Annals of Oncology. 27. vi430–vi430. 1 indexed citations
15.
Gossiel, Fatma, Christopher Hoyle, Eugène McCloskey, et al.. (2016). The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone. 92. 94–99. 31 indexed citations
16.
Hoyle, Christopher, et al.. (2016). Mapping the COPD Assessment Test onto EQ-5D. Value in Health. 19(4). 469–477. 13 indexed citations
17.
Herdman, Michael, et al.. (2015). Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health. 19(2). 255–266. 14 indexed citations
18.
19.
20.
Pavesi, Marco, Nancy Devlin, Zalmaï Hakimi, et al.. (2013). Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron. Journal of Medical Economics. 16(7). 866–876. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Bancos Breakdown of academic impact, for papers by Ruizhen Jia Breakdown of academic impact, for papers by Shuang Yin Breakdown of academic impact, for papers by Jin Zhou Breakdown of academic impact, for papers by Rongpan Bai Breakdown of academic impact, for papers by Zhenzhen Deng Breakdown of academic impact, for papers by Alena V. Savenka Breakdown of academic impact, for papers by Chuang Yuan Breakdown of academic impact, for papers by Kamlakar Tripathi Breakdown of academic impact, for papers by Fatemeh Hassani
Rankless by CCL
2026